vTv Therapeutics director granted 6,000 stock options

vTv Therapeutics Inc. director Anne M. Phillips received a grant of options to buy 6,000 shares of Class A common stock at an exercise price of $35.08 per share.

Rhea-AI Filing Summary

vTv Therapeutics Inc. director Anne M. Phillips received a grant of options to buy 6,000 shares of Class A common stock at an exercise price of $35.08 per share. These director stock options expire on June 26, 2036 and are part of her board compensation.

The option vests on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of shareholders, provided she continues serving on the board through that date. Following this grant, she holds options covering 16,860 shares directly.

Insider Trade Summary

Grant/Award: 6,000 shares

Grant/Award 1 txn

Insider Phillips Anne M.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director stock option (right to buy)	6,000	$35.08	$210K

Holdings After Transaction: Director stock option (right to buy) — 16,860 contracts (Direct)

Footnotes (1)

1. F1. The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.

Key Figures

Option grant size: 6,000 options Exercise price: $35.08 per share Options after grant: 16,860 options +2 more

5 metrics

Option grant size 6,000 options Director stock option grant to Anne M. Phillips

Exercise price $35.08 per share Director stock option strike price

Options after grant 16,860 options Total derivative securities held directly post-transaction

Option expiration June 26, 2036 Director stock option expiration date

Vesting date Earlier of June 26, 2027 or 2027 AGM Subject to continued board service

Key Terms

Director stock option (right to buy), Class A Common Stock, annual general meeting of shareholders, vests, +1 more

5 terms

Director stock option (right to buy) financial

"security_title: Director stock option (right to buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

annual general meeting of shareholders financial

"the date of the 2027 annual general meeting of shareholders"

vests financial

"The option vests on the earlier of June 26, 2027"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did vTv Therapeutics (VTVT) director Anne M. Phillips report on this Form 4?

Anne M. Phillips reported receiving a grant of director stock options for 6,000 shares at an exercise price of $35.08 per share. The options relate to vTv Therapeutics Class A common stock and are structured as part of her compensation for serving on the board.

What are the key terms of the vTv Therapeutics (VTVT) director stock options granted to Anne M. Phillips?

The grant covers 6,000 options with an exercise price of $35.08 per share and an expiration date of June 26, 2036. The options give the right to purchase vTv Therapeutics Class A common stock if the vesting conditions are met and she chooses to exercise.

When do Anne M. Phillips’ vTv Therapeutics (VTVT) stock options vest according to the Form 4?

The director stock option vests on the earlier of June 26, 2027 and the date of vTv Therapeutics’ 2027 annual general meeting of shareholders. Vesting is conditioned on her continued service on the board of directors through the applicable vesting date, as described in the filing.

How many vTv Therapeutics (VTVT) derivative securities does Anne M. Phillips hold after this option grant?

After receiving the 6,000 director stock options, Anne M. Phillips holds derivative securities covering 16,860 shares of Class A common stock. These holdings reflect her direct ownership of options following the reported grant, as stated in the post-transaction share balance on the Form 4.

Is the vTv Therapeutics (VTVT) Form 4 transaction an open-market stock purchase or sale?

The Form 4 reports a grant of director stock options, not an open-market purchase or sale of common shares. The transaction code is “A,” indicating a grant, award, or other acquisition of derivative securities as compensation rather than a discretionary trade in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Phillips Anne M.

(Last) (First) (Middle)

C/O VTV THERAPEUTICS INC.

3980 PREMIER DRIVE, SUITE 110

(Street)

HIGH POINT NORTH CAROLINA 27265

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
vTv Therapeutics Inc. [ VTVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director stock option (right to buy)	$35.08	06/26/2026		A		6,000		(1)	06/26/2036	Class A Common Stock	6,000	$35.08	16,860	D

Explanation of Responses:

1. The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.

Remarks:

	/s/ Elizabeth Keiley, as Attorney-in-fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)